Chronicle Specials + Font Resize -

NPPA fixes price for formulation packs; revises conversion, packaging costs
Our Bureau, Mumbai | Thursday, December 27, 2007, 08:00 Hrs  [IST]

The National Pharmaceutical Pricing Authority (NPPA) has revised or fixed the price of 164 formulation packs, including ceiling prices of 119 different sizes and strengths of bulk drugs and combinations. The authority has also revised the norms prescribed for conversion cost, packaging charges, process loss of raw materials and packing material cost of pharmaceutical products through a notification dated November 30, 2007.

The revised non ceiling price drugs includes various strengths and forms of imported medicines like Depo Medrol injection, Solu Medrol injection and Medrol tablet from Pfizer Products India Ltd, Novorapid from Novo Nordisk India Pvt Ltd, Daivobet ointment from Win-Medicare Pvt Ltd, various strengths of Monocomponent Insulin from Eli-Lilly and Company (I) Pvt Ltd and price of Madopar from Nicholas Piramal India Ltd. The prices of Novalgin tablet and injection from sanofi aventis has also been reviewed by the authority.

NPPA has fixed price for five formulation packs, for two forms of framycetin cream, streptomycin sulphate+procaine penicillin G+ penicillin G sodium injection, analgin+phenyl butazone+ lignocaine HCl+ benzyl alcohol injection and oxytetracycline+lidocaine injection, considering as new cases in the list.

The authority has also revised 27 formulation packages of various strengths and forms of naproxen and naproxen sodium under Suo-Moto action. Apart, the authority has also fixed price of 60 new formulation packs of various strength, form and combination of bulk drugs including multivitamin syrup and tablet, methyl prednisolone injection, dexamethasone+ofloxacin+benzalkonium chloride drops, erythromycin eye ointment etc.

NPPA's annual revision of conversion cost, packaging charges, process loss of raw materials and packing material cost of pharmaceutical products falls in lines with its policy has also notified with the revision of bulk drugs. The conversion cost, packaging charges and process loss of raw materials will continue to be the same rate fixed last year, while the packing material cost has undergone some slight increase with immediate effect.

Post Your Comment

 

Enquiry Form